Adjuvant treatment of breast cancer: impact of monoclonal antibody therapy directed against the HER2 receptor

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.7, Iss.4, 2007-04, pp. : 487-491

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HER2 as a target for breast cancer therapy

By Tagliabue Elda Balsari Andrea Campiglio Manuela Pupa Serenella M

Expert Opinion on Biological Therapy, Vol. 10, Iss. 5, 2010-05 ,pp. : 711-724

Informa Healthcare

Access to resources Recommend Favorite

Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults

By Bajaj Madhuri Heath Elisabeth I

Expert Opinion on Biological Therapy, Vol. 11, Iss. 11, 2011-11 ,pp. : 1519-1524

Informa Healthcare

Access to resources Recommend Favorite

Antibody-directed enzyme prodrug therapy (ADEPT) for cancer

By Bagshawe Kenneth D Sharma Surinder K Begent Richard HJ

Expert Opinion on Biological Therapy, Vol. 4, Iss. 11, 2004-11 ,pp. : 1777-1789

Informa Healthcare

Access to resources Recommend Favorite

IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer

By Herbst Roy S Kim Edward S Harari Paul M

Expert Opinion on Biological Therapy, Vol. 1, Iss. 4, 2001-07 ,pp. : 719-732

Informa Healthcare

Access to resources Recommend Favorite

Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer

By Burris Howard A

Expert Opinion on Biological Therapy, Vol. 11, Iss. 6, 2011-06 ,pp. : 807-819

Informa Healthcare

Access to resources Recommend Favorite